SecBot SecBot
Biotech Drug Report Generated Nov 18, 2026

ZILRETTA

PCRX·Pacira BioSciences, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (Phase 3 for shoulder osteoarthritis indication expansion)
Time to market
ZILRETTA is already FDA-approved and commercially available for osteoarthritis knee pain (approved October 2017). A label expansion for shoulder osteoarthritis is contingent on the ongoing Phase 3 study (estimated primary completion December 2026), with potential FDA filing thereafter.
Why 3/10
ZILRETTA is an already-approved, marketed drug with no pending FDA regulatory decision. The next hard catalyst is the Phase 3 shoulder osteoarthritis topline readout (estimated primary completion December 2026), but this now matters for acquirer Viatris (VTRS), not PCRX shareholders whose stock is being cashed out at $36.50/share following today's deal close. ImpactScore is 3: an approved drug with no binary regulatory catalyst for the original developer.
Actionable Insight NEUTRAL

ZILRETTA's next catalyst is the Phase 3 shoulder osteoarthritis readout (NCT06269705, estimated primary completion December 2026). However, with Pacira's acquisition by Viatris closing today at $36.50/share, this readout now matters for VTRS shareholders, not PCRX holders who are being cashed out at essentially the current $36.48 price. Watch for Viatris integration updates and whether the J&J MedTech co-promotion partnership continues post-acquisition.

Price Chart

Loading chart...

Executive Summary

ZILRETTA is an FDA-approved extended-release corticosteroid injection for osteoarthritis knee pain, developed by Pacira BioSciences (PCRX). It was originally developed by Flexion Therapeutics and approved in October 2017. The drug uses microsphere technology to provide sustained pain relief from a single injection. ZILRETTA generated roughly $26.8M in Q1 2026 sales (up 15% YoY), representing about 15% of Pacira's total revenue. A Phase 3 registrational study for shoulder (glenohumeral) osteoarthritis completed enrollment in early 2026 with estimated primary completion in December 2026. Critically, Viatris (VTRS) completed its $1.65B acquisition of Pacira today (Nov 17, 2026) at $36.50/share, meaning PCRX stock is now locked at the deal price with no further upside for legacy shareholders.

How It Works

ZILRETTA is an extended-release formulation of a corticosteroid (triamcinolone acetonide) injected directly into the knee joint. The drug is encapsulated in microscopic polymer spheres (microspheres) that slowly release the medication over time, providing sustained pain relief from osteoarthritis for up to 12 weeks with a single injection. This contrasts with standard steroid shots that release the drug quickly and may only last a few weeks.

Trial Status

ZILRETTA is approved and marketed for osteoarthritis knee pain. A Phase 3 registrational study for shoulder (glenohumeral) osteoarthritis (NCT06269705, n=150) completed enrollment in Q1 2026 and is active but not recruiting, with estimated primary completion in December 2026. A Phase 2 hip osteoarthritis study was previously terminated. The company also presented real-world data on EXPAREL (a related product) at AMCP 2026.

The Two-Sided Case

▲ Bull Case4
ZILRETTA is already FDA-approved and commercially established for osteoarthritis knee pain, providing a recurring revenue stream with Q1 2026 sales up 15% YoY to $26.8M.
A strategic co-promotion partnership with Johnson & Johnson MedTech (announced July 2025) was expanding ZILRETTA's reach to primary care and orthopedic audiences.
The Phase 3 registrational study for shoulder (glenohumeral) osteoarthritis (enrollment completed Q1 2026, estimated primary completion Dec 2026) could open a new indication and expand the addressable market.
Viatris completed its $1.65B acquisition of Pacira today (Nov 17, 2026), projecting a $100M revenue boost from the combined non-opioid pain portfolio including ZILRETTA.
▼ Bear Case4
ZILRETTA is a relatively small contributor to Pacira's revenue (roughly 15% of total, ~$26.8M in Q1 2026), limiting its standalone impact on the combined Viatris entity.
A Phase 2 hip osteoarthritis study was terminated, and the Phase 3 shoulder OA readout (estimated Dec 2026) carries clinical and regulatory risk for label expansion.
The drug faces competition from standard corticosteroid injections, hyaluronic acid viscosupplements, and newer osteoarthritis treatments including regenerative therapies.
PCRX stock is now locked at the $36.50 acquisition price with the deal closing today; there is no further upside for PCRX shareholders regardless of ZILRETTA's future performance.

Upcoming Catalysts

  • Phase 3 shoulder osteoarthritis topline readout (estimated primary completion December 2026, NCT06269705)
  • Viatris integration and commercial strategy updates for ZILRETTA following the acquisition close (Nov 17, 2026)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Pacira BioSciences, Inc. 8-K PCRX ·Originating report

Sources · 8

Hover a chip for the title
1 bizjournals.com2 bizjournals.com3 beckershospitalreview.com4 natlawreview.com5 manilatimes.net6 msn.com7 seekingalpha.com8 morningstar.com